Tenax Therapeutics Stock (NASDAQ:TENX)
Previous Close
$5.80
52W Range
$2.77 - $27.36
50D Avg
$4.77
200D Avg
$3.91
Market Cap
$19.81M
Avg Vol (3M)
$64.27K
Beta
2.15
Div Yield
-
TENX Company Profile
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
TENX Performance
Peer Comparison
| Ticker | Company |
|---|---|
| ZVSA | ZyVersa Therapeutics, Inc. |
| ENSC | Ensysce Biosciences, Inc. |
| ADTX | Aditxt, Inc. |
| REVB | Revelation Biosciences, Inc. |
| QNRX | Quoin Pharmaceuticals, Ltd. |
| DRMA | Dermata Therapeutics, Inc. |
| VRAX | Virax Biolabs Group Limited |
| ALLR | Allarity Therapeutics, Inc. |
| CYTO | Altamira Therapeutics Ltd. |
| NRBO | NeuroBo Pharmaceuticals, Inc. |
| SONN | Sonnet BioTherapeutics Holdings, Inc. |
| WINT | Windtree Therapeutics, Inc. |
| UNCY | Unicycive Therapeutics, Inc. |